High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Brain Neoplasms
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
  • Meningeal Neoplasms
  • Quinazolines

abstract

  • The CNS was a frequent site of disease recurrence in patients with NSCLC after an initial response to gefitinib, regardless of disease control in the lungs. Patients should be carefully monitored for neurologic symptoms. Intrinsic resistance of metastatic clones, incomplete CNS penetrance of the drug, and longer survival are possible explanations for this high incidence.

publication date

  • June 2005

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/cncr.21033

PubMed ID

  • 15844174

Additional Document Info

start page

  • 2344

end page

  • 8

volume

  • 103

number

  • 11